Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.57 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12327788 | 0.86 | AXL (0.62) | AXLPPARDCYP2A6KEAP1PDGFRB | |
| SCHEMBL16756015 | 0.83 | AXL (0.62) | AXLPPARDCYP2A6KEAP1PDGFRB | |
| SCHEMBL22300369 | 0.81 | AXL (0.65) | AXLPPARDCYP2A6KEAP1PDGFRB | |
| SCHEMBL13344896 | 0.81 | AXL (0.60) | AXLPPARDCYP2A6KEAP1PDGFRB | |
| SCHEMBL9272429 | 0.79 | PPARD (0.52) | AXLPPARDCYP2A6KEAP1PDGFRB | |
| SCHEMBL8292832 | 0.79 | AXL (0.66) | AXLPPARDCYP2A6KEAP1PDGFRB | |
| SCHEMBL13344928 | 0.79 | PDGFRB (0.60) | AXLPPARDCYP2A6KEAP1PDGFRB | |
| SCHEMBL9277759 | 0.78 | PPARD (0.51) | AXLPPARDCYP2A6KEAP1PDGFRB | |
| SCHEMBL9277763 | 0.78 | AXL (0.49) | AXLPPARDCYP2A6KEAP1PDGFRB | |
| SCHEMBL7802190 | 0.78 | PDE3B (0.51) | PDGFRBPDGFRAALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349833-B1 | INDOLE AND DIHYDROINDOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-04-19 | — | — | EP | disclosed |
| CN-1245385-C | indole and indoline derivatives | HOFFMANN LA ROCHE (CH) | 2006-03-15 | — | — | CN | disclosed |
| CN-1733723-A | Indole and dihydroindole derivatives | HOFFMANN LA ROCHE (CH) | 2006-02-15 | — | — | CN | disclosed |
| CN-1476432-A | indole and indoline derivatives | - | 2004-02-18 | — | — | CN | disclosed |
| EP-1349833-A1 | INDOLE AND DIHYDROINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-08 | — | — | EP | disclosed |
| US-6503907-B2 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | HOFFMANN-LA ROCHE INC. | 2003-01-07 | — | — | US | disclosed |
| US-20020103247-A1 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | HOFFMANN-LA ROCHE INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002044149-A1 | INDOLE AND DIHYDROINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-06 | — | — | WO | disclosed |
| US-5468641-A | Device for validating urobilinogen test devices | BAYER CORPORATION (US) | 1995-11-21 | — | — | US | disclosed |
| EP-0628821-A2 | Device for validating urobilinogen test devices | Bayer Corporation (US) | 1994-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103247-A1 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | LSS, CYP51A1, DHCR7 | AXL 4303/4885PPARD 2024/4885CYP2A6 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.